2. Search Result
Search Result
Results for "

control

" in MCE Product Catalog:

439

Inhibitors & Agonists

17

Screening Libraries

4

Fluorescent Dye

11

Biochemical Assay Reagents

78

Peptides

1

MCE Kits

3

Inhibitory Antibodies

32

Natural
Products

2

Recombinant Proteins

80

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Area
  • HY-P4124
    Pepinh-Control

    		Peptides Others
    Pepinh-Control is a negative control peptide.
  • HY-P1383A
    Rac1 Inhibitor F56, control peptide TFA

    		Peptides Others
    Rac1 Inhibitor F56, control peptide TFA is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor F56, control peptide TFA contains a Trp 56 to Phe 56 mutation. Rac1 Inhibitor F56, control peptide TFA has no effect on Rac1 interaction with its guanine nucleotide exchange factors (GEFs).
  • HY-P2250
    ELA RR>GG

    ELA-32 negative control

    		 Peptides Others
    ELA RR>GG (ELA-32 negative control), an ELABELA (ELA-32 human) mutant peptide, is inactive. ELA RR>GG is a negative control for ELABELA (HY-P2196).
  • HY-P4907
    RGD Negative Control

    		Peptides Others
    RGD Negative Control is the negative control of RGD (HY-P0278).
  • HY-P2248
    ELA-14 negative control

    		Peptides Others
    ELA-14 negative control, a peptide, is inactive. ELA-14 negative control is a negative control for ELA-14.
  • HY-P3708
    TRAF6 control peptide

    		Peptides Others
    TRAF6 control peptide is a control peptide for TRAF6.
  • HY-P1398
    Compstatin control peptide

    		Peptides Inflammation/Immunology
    Compstatin control peptide is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
  • HY-P1398A
    Compstatin control peptide TFA

    		Peptides Inflammation/Immunology
    Compstatin control peptide TFA is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
  • HY-P0301
    SLLK, Control Peptide for TSP1 Inhibitor

    		Peptides Cancer
    SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).
  • HY-P1897
    Fibronectin Active Fragment Control

    		Peptides Inflammation/Immunology
    Fibronectin Active Fragment Control is an active peptide fragment of fibronectin. Fibronectin is a glycoprotein interacting with integrins.
  • HY-P0301A
    SLLK, Control Peptide for TSP1 Inhibitor(TFA)

    		Peptides Cancer
    SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.
  • HY-P1383
    Rac1 Inhibitor F56, control peptide

    		Peptides Others
    Rac1 Inhibitor F56, control peptide is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor F56, control peptide contains a Trp 56 to Phe 56 mutation. Rac1 Inhibitor F56, control peptide has no effect on Rac1 interaction with its guanine nucleotide exchange factors (GEFs).
  • HY-P5119
    Tat-peptide control 168-189

    		Peptides Neurological Disease
    Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron.
  • HY-P5119A
    Tat-peptide control 168-189 TFA

    		Peptides Neurological Disease
    Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron.
  • HY-P1849
    JAG-1, scrambled

    scJag-1

    		 Peptides Cardiovascular Disease
    JAG-1, scrambled (scJag-1) is a scrambled sequence of JAG-1 (Jagged-1 protein). JAG-1, scrambled has a random sequence of the amino acids that are the same as the active fragment. JAG-1, scrambled is usually used as a negative control.
  • HY-P1849A
    JAG-1, scrambled TFA

    scJag-1 TFA

    		 Peptides Cardiovascular Disease
    JAG-1, scrambled (scJag-1) TFA is a scrambled sequence of JAG-1 (Jagged-1 protein). JAG-1, scrambled TFA has a random sequence of the amino acids that are the same as the active fragment. JAG-1, scrambled TFA is usually used as a negative control.
  • HY-P2039
    Retrobradykinin

    		Bradykinin Receptor Endogenous Metabolite Endocrinology Cardiovascular Disease
    Retrobradykinin has the reverse sequence of Bradykinin (HY-P0206). Retrobradykinin exhibits no kinin activity and can be used as a negative control for Bradykinin.
  • HY-P3460
    TDSRCVIGLYHPPLQVY

    		Peptides Inflammation/Immunology Neurological Disease Cardiovascular Disease
    TDSRCVIGLYHPPLQVY is a disordered control peptide. TDSRCVIGLYHPPLQVY is a peptide containing the same amino acids as LP17 (HY-P3400) but in a different sequence order.
  • HY-P1513A
    LL-37 scrambled peptide acetate

    		Bacterial Infection
    LL-37 scrambled peptide acetate is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide acetate can be used as a negative control of LL-37 peptide studies.
  • HY-P3460A
    TDSRCVIGLYHPPLQVY TFA

    		Peptides Inflammation/Immunology Neurological Disease Cardiovascular Disease
    TDSRCVIGLYHPPLQVY TFA is a disordered control peptide. TDSRCVIGLYHPPLQVY TFA is a peptide containing the same amino acids as LP17 (HY-P3400) but in a different sequence order.
  • HY-P1310
    VKGILS-NH2

    		Protease Activated Receptor (PAR) Inflammation/Immunology
    VKGILS-NH2 is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 has no effect on DNA synthesis in cells.
  • HY-P1310A
    VKGILS-NH2 TFA

    		Protease Activated Receptor (PAR) Inflammation/Immunology
    VKGILS-NH2 TFA is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 TFA has no effect on DNA synthesis in cells.
  • HY-P1402
    [Glu27]-PKC (19-36)

    		Peptides Others
    [Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids.
  • HY-P3463
    Beinaglutide

    GLP-1 (human)

    		 GCGR Metabolic Disease Inflammation/Immunology
    Beinaglutide is a recombinant human GLP-1 (rhGLP-1) polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
  • HY-109556
    Insulin Detemir

    		Akt ERK Metabolic Disease
    Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.
  • HY-P3893
    PSTAIR

    		CDK Metabolic Disease
    PSTAIR is a monoclonal antibody that recognizes the PSTAIR sequence in Cdc28, PSTAIR can be used as loading control.
  • HY-P2198
    PAMP-12(human, porcine)

    		Peptides Cardiovascular Disease
    PAMP-12(human, porcine) is a major component of immunoreactive (ir)-PAMP, is processed from the adrenomedullin precursor, is a potent hypotensive peptide and participates in cardiovascular control.
  • HY-P2198A
    PAMP-12(human, porcine) TFA

    		Peptides Cardiovascular Disease
    PAMP-12(human, porcine) TFA is a major component of immunoreactive (ir)-PAMP, is processed from the adrenomedullin precursor, is a potent hypotensive peptide and participates in cardiovascular control.
  • HY-P3155
    Ac-hMCH(6-16)-NH2

    		MCHR1 (GPR24) Metabolic Disease
    Ac-hMCH(6-16)-NH2 binds to and activates equally well both human MCH receptors present in the brain (non-selective agonist), with IC50 values of 0.16 nM and 2.7 nM for MCH-1R and MCH-2R.
  • HY-P1391
    ZIP(Scrambled)

    		Peptides Others
    ZIP(Scrambled) is a scrambled control peptide for zeta inhibitory peptide (ZIP).
  • HY-P0231
    AZP-531

    		GHSR Metabolic Disease Endocrinology
    AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.
  • HY-P2547
    Tyrosine Kinase Peptide 1

    		Src Others
    Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay.
  • HY-P1391A
    ZIP(Scrambled) TFA

    		Peptides Others
    ZIP(Scrambled) TFA is a scrambled control peptide for zeta inhibitory peptide (ZIP).
  • HY-P0232
    Fmoc-Thr[GalNAc(Ac)3-α-D]-OH

    Fmoc-Thr(Ac₃AcNH-α-Gal)-OH

    		 Amino Acid Derivatives Cancer Inflammation/Immunology
    AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.
  • HY-P0002A
    Protirelin acetate

    Thyrotropin-releasing-hormone acetate; TRH acetate

    		 Thyroid Hormone Receptor Endocrinology Inflammation/Immunology
    Protirelin Acetate is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.
  • HY-P0309
    Arg-Gly-Glu-Ser

    		Peptides Cancer
    Arg-Gly-Glu-Ser is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.
  • HY-P1311
    RLLFT-NH2

    		Peptides Others
    RLLFT-NH2 is a reversed amino acid sequence negative control peptide for TFLLR-NH2.
  • HY-P4232
    H-Gly-Arg-Ala-Asp-Ser-Pro-OH

    		Peptides Others
    H-Gly-Arg-Ala-Asp-Ser-Pro-OH (GRADSP) is a negative control peptide of GRGDdSP.
  • HY-P0002
    Protirelin

    Thyrotropin-releasing-hormone; TRH

    		 Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Inflammation/Immunology
    Protirelin is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.
  • HY-P1311A
    RLLFT-NH2 TFA

    		Peptides Others
    RLLFT-NH2 TFA is a reversed amino acid sequence negative control peptide for TFLLR-NH2.
  • HY-P0309A
    Arg-Gly-Glu-Ser TFA

    		Peptides Others
    Arg-Gly-Glu-Ser TFA is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.
  • HY-P0243
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon

    Salmon GnRH; Salmon gonadotropin-releasing hormone; sGnRH

    		 Peptides Metabolic Disease
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon (Salmon GnRH) is the hypophysiotropic decapeptide synthesized in the hypothalamus that plays a crucial role in the control of reproductive functions.
  • HY-P4062
    Insulin peglispro

    BIL

    		 Insulin Receptor Metabolic Disease
    Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins.
  • HY-P2004
    FFAGLDD

    		MMP Cancer
    FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release.
  • HY-P2517
    Scrambled TRAP Fragment

    		Peptides Others
    Scrambled TRAP Fragment is a scrambled sequence of TRAP Fragment. Scrambled TRAP Fragment with a random sequence of the amino acids that are the same as the active fragment. Scrambled TRAP Fragment usually used as a negative control.
  • HY-P2004A
    FFAGLDD TFA

    		MMP Cancer
    FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release.
  • HY-P3089
    Dendrotoxin K

    		Potassium Channel Others
    Dendrotoxin K is a Kv1.1 channel blocker. Dendrotoxin K determines glutamate release in CA3 neurons in a time-dependent manner through the control of the presynaptic spike waveform.
  • HY-P3842
    Protein Kinase C (661-671)

    		PKC Cancer
    Protein Kinase C (661-671) is a fragment peptide of β1 subspecies of protein kinase C (PKC). PKC plays a role in cellular growth control and tumor promotion.
  • HY-P2360
    G12

    Ras 5-17

    		 Peptides Others
    G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12).
  • HY-P2361A
    S12 TFA

    		Peptides Others
    G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12).
  • HY-P1513
    LL-37 scrambled peptide

    		Bacterial Infection
    LL-37 scrambled peptide is a scrambled version of cathelicidin anti-microbial peptide LL-37. LL-37 scrambled peptide can be used as a negative control of LL-37 peptide studies.
  • HY-P2360A
    G12 TFA

    Ras 5-17 TFA

    		 Peptides Others
    G12 (Ras 5-17) TFA is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 TFA can be used as a control of mutant Ras peptides studies (such V12).
  • HY-P1312
    LRGILS-NH2

    		Peptides Others
    LRGILS-NH2 is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.
  • HY-P1312A
    LRGILS-NH2 TFA

    		Peptides Others
    LRGILS-NH2 TFA is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.
  • HY-P3765
    Auriculin A

    		Peptides Cardiovascular Disease
    Auriculin A is a synthetic atrial natriuretic factor (ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits.
  • HY-P4114
    TAT-NSF700scr

    		HIV Others
    TAT-NSF700scr consists the intact TAT domain and glycine linker, followed by the NSF amino acids in a random order. TAT-NSF700scr is used as a control peptide that does not inhibit SNAREmediated exocytosis.
  • HY-114174
    Fmoc-Ala-Glu-Asn-Lys-NH2

    		Amyloid-β Neurological Disease
    Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloid precursor protein (APP) cleavage. AEP, a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing.
  • HY-P3720
    YEQLRNSRA

    		Peptides Cancer
    YEQLRNSRA is a MycC Peptide. MycC Peptide is encoded by c-myc proto-oncogene, the c-myc oncogene has been implicated in malignant progression in a variety of human tumors. MycC Peptide regulates fundamental cellular processes like growth control, metabolism, proliferation, differentiation, and apoptosis.
  • HY-P4564
    (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH

    		GnRH Receptor Endocrinology
    (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
  • HY-P4568
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH

    		GnRH Receptor Endocrinology
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
  • HY-P3882
    Fmoc-Ala-Glu-Gln-Lys-NH2

    		Amino Acid Derivatives Neurological Disease
    Fmoc-Ala-Glu-Gln-Lys-NH2 (AEQK) is a tetrapeptide. Fmoc-Ala-Glu-Gln-Lys-NH2 is the inactive control for Fmoc-Ala-Glu-Asn-Lys-NH2 (AENK) peptide inhibitor. AENK blocks proteolysis of UNC5C protein.
  • HY-P4577
    (D-Tyr5,D-Ser(tBu)6,Azagly10)-LHRH

    		GnRH Receptor Endocrinology
    (D-Tyr5,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
  • HY-P4112
    TAT-NSF222scr Fusion Polypeptide, scrambled

    		Peptides Others
    TAT-NSF222scr Fusion Polypeptide, scrambled is a control peptide of TAT-NSF700 Fusion Peptide (HY-P4113). TAT-NSF222scr Fusion Polypeptide, scrambled is consisted of the intact TAT domain followed by the amino acid residues of NSF 222-243 in a scrambled order.
  • HY-12554A
    Terlipressin acetate

    		Vasopressin Receptor Endocrinology Inflammation/Immunology Cardiovascular Disease
    Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.
  • HY-P2537
    Apelin-12

    		HIV Others
    Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect.
  • HY-P2231
    Cotadutide

    MEDI0382

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D).
  • HY-P2231A
    Cotadutide acetate

    MEDI0382 acetate

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D).
  • HY-P3570
    Adipokinetic hormone II (Locusta migratoria)

    Lom-AKH-II

    		 Endogenous Metabolite Metabolic Disease
    Adipokinetic hormone II (Locusta migratoria) (Lom-AKH-II) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs).
  • HY-P3572
    Adipokinetic hormone I (Locusta migratoria)

    Lom-AKH-I

    		 Endogenous Metabolite Endocrinology
    Adipokinetic hormone I (Locusta migratoria) (Lom-AKH-I) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs).
  • HY-P1075
    CALP3

    		Calcium Channel Cancer Neurological Disease
    CALP3, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
  • HY-P2511
    Insulin β Chain Peptide (15-23)

    		Peptides Metabolic Disease
    Insulin β Chain Peptide (15-23), also known as INS, is an insulin-derived peptide recognized by islet-associated T cells. The Insulin β Chain Peptide (15-23) tetramer stained the INS-reactive CTL clone G9C8, but neither this tetramer nor the negative control tetramer (TUM) stained the splenic CD8+ T cells from NOD or 8.3-TCRαβtransgenic NOD mice.
  • HY-P1075A
    CALP3 TFA

    		Calcium Channel Cancer Neurological Disease
    CALP3 TFA, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
  • HY-P1746A
    Protein Kinase C (19-31) (TFA)

    PKC (19-31) (TFA)

    		 PKC Inflammation/Immunology
    Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing the protein kinase C activity. Protein kinase C (PKC) TFA is involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins.
  • HY-P1746
    Protein Kinase C (19-31)

    PKC (19-31)

    		 PKC Inflammation/Immunology
    Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing the protein kinase C activity. Protein kinase C (PKC) is involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins.
  • HY-P3019
    Urocortin III (human)

    		CRFR Endocrinology Neurological Disease Cardiovascular Disease
    Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with Ki values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion.
  • HY-P2260B
    Tat-beclin 1 scrambled

    		Peptides Infection
    Tat-beclin 1 scrambled is the scrambled part and a scrambled control of Tat-beclin 1 (HY-P2260), which is derived from a region of the autophagy protein, beclin 1. beclin 1 induces autophagy via binding human immunodeficiency virus, HIV-1 Nef and interacting with negative regulator GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens, such as HIV-1. Tat-beclin 1 also reduces mortality in mice infected with chikungunya or West Nile virus.
  • HY-P2260C
    Tat-beclin 1 scrambled TFA

    		Peptides Infection
    Tat-beclin 1 scrambled TFA is the scrambled part and a scrambled control of Tat-beclin 1 (HY-P2260), which is derived from a region of the autophagy protein, beclin 1. beclin 1 induces autophagy via binding human immunodeficiency virus, HIV-1 Nef and interacting with negative regulator GAPR-1 (GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens, such as HIV-1. Tat-beclin 1 also reduces mortality in mice infected with chikungunya or West Nile virus.
  • HY-P2307
    Tat-NR2Baa

    		iGluR NO Synthase Neurological Disease
    Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95.